Mar 20, 2026 | Novartis $2B Bet on PI3Kα in Breast Cancer; Opdivo Approved for Hodgkin Lymphoma

Novartis pays $2B upfront for Synnovation's Phase 1/2 PI3Kα inhibitor SNV4818 to defend its HR+/HER2- breast cancer franchise. Plus: BMS Opdivo wins first immunotherapy combo approval in frontline Hodgkin lymphoma, GSK's Lynavoy becomes first drug for cholestatic pruritus in PBC, and Pfizer's TALAPRO-3 clears Phase 3 in prostate cancer.Visit us at: https://thepharmacloseout.com/pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Novartis,Synnovation Therapeutics, PI3K alpha inhibitor, SNV4818, breast cancer, HR+HER2-, Bristol Myers Squibb, BMS, Opdivo, nivolumab, Hodgkin lymphoma, GSK,linerixibat, Lynavoy, primary biliary cholangitis, PBC, cholestatic pruritus,Pfizer, Talzenna, talazoparib, Xtandi, enzalutamide, prostate cancer,TALAPRO-3, Collegium, Azstarys, ADHD, Rhythm Pharmaceuticals, IMCIVREE, setmelanotide,Genentech, Roche, emugrobart, obesity, Earendil, AI biotech, Lilly